#liquidbiopsy

Rising prevalence of chronic diseases, increasing investment in life sciences research, expanding applications in diagnostics and therapeutics, and rapid advancements in exosome isolation technologies are driving strong growth in the exosome research market.

The global Exosome Research Market size was valued at USD 222.4 million in 2024, with an estimation of USD 262.9 million in 2025 and is predicted to reach USD 606.6 million by 2030 with a CAGR of 18.2% from 2025-2030. 

Download FREE Sample

Researchers are increasingly utilizing exosomes as biomarkers for early disease detection and as novel drug delivery vehicles due to their ability to transport proteins, lipids, and genetic material with high specificity. Growing interest in liquid biopsy technologies, regenerative medicine, and cell free therapeutics is creating new opportunities for market participants. Technological innovations in microfluidics, nanotechnology, and artificial intelligence driven data analysis are also enhancing exosome research capabilities and supporting the development of next generation biomedical solutions.

Key Players

• NanoSomiX, Inc.

• Bio-Techne Corporation

• Thermo Fisher Scientific Inc.

• Malvern Panalytical

• System Biosciences, LLC.

• Capricor Therapeutics, Inc.

• Miltenyi Biotec

• RoosterBio, Inc.

• NX Pharmagen

• Lonza Group AG

• AMS Biotechnology (Europe) Limited

• Exosome Diagnostics, Inc.

• EXO Biologics

• Evox Therapeutics Ltd.

• QIAGEN N.V.

Competitive Landscape

The market is moderately competitive, with leading biotechnology companies, life sciences organizations, and research tool manufacturers investing in advanced exosome isolation technologies, analytical platforms, and innovative research solutions. Companies are focusing on expanding their product portfolios while improving workflow efficiency, reproducibility, and scalability to support the growing demand for exosome based research across academic and commercial laboratories.

Conclusion

🔬 Session Highlight: Liquid Biopsies & Early Detection

Early detection is transforming the future of cancer care, and liquid biopsies are at the forefront of this revolution. This session at the 11th International Congress on Cancer Science and Radiology 2026 will explore how minimally invasive diagnostic techniques are enabling faster, more accurate detection and monitoring of cancer.

Join leading experts as they discuss advancements in circulating tumor DNA (ctDNA), biomarker discovery, and real-time disease tracking—paving the way for personalized treatment strategies and improved patient outcomes.

📅 July 22–23, 2026 📍 Hilton Tokyo Hotel, Tokyo, Japan

🌐 https://cancertherapy.inovineconferences.com/

The breast cancer liquid biopsy market size was exhibited at USD 1.45 billion in 2025 and is projected to hit around USD 3.09 billion by 2035, growing at a CAGR of 7.86% during the forecast period 2026 to 2035. The breast cancer liquid biopsy market growth can be linked to the globally rising breast cancer cases, need for effective early detection solutions, increasing preference for non-invasive procedures, and ongoing launches of innovative liquid biopsy assays and kits.

🔍 Key trends shaping the space

Expansion of companion diagnostics with targeted therapies

AI-powered analysis improving accuracy and reducing false results

Multi-biomarker panels boosting diagnostic confidence

Growing use in early-stage detection and high-risk screening

The global lung cancer liquid biopsy market was valued at USD 1.02 billion in 2024 and is expected to rise to USD 1.15 billion in 2025. Looking ahead, the market is forecast to reach USD 3.49 billion by 2034, growing at an impressive CAGR of 13.1% from 2025 to 2034.

This strong growth is driven by the increasing prevalence of lung cancer, the rising shift toward non-invasive diagnostic methods, rapid technological progress in next-generation sequencing (NGS) and digital PCR, and the expanding adoption of personalized medicine across oncology care.

Why Liquid Biopsy Matters

Liquid biopsy is redefining lung cancer care through:

Faster diagnosis

Lower cost compared to surgical biopsies

Better treatment decisions through targeted biomarker profiling

Continuous monitoring without invasive procedures

Survival rates soar when cancer is found early. At Advanced Wellness MD, we don't wait for symptoms—we empower you with advanced, proactive Cancer Detection protocols.

From cutting-edge Liquid Biopsies to comprehensive Multi-Cancer Early Detection (MCED) Tests, we look deeper to give you peace of mind and the best chance at a long, healthy life.

Don't be reactive, be proactive.

Learn more about our life-saving protocols and schedule your consultation: https://advancedwellmd.com/

The world of cancer research is undergoing a powerful transformation, and at the heart of it lies Circulating Tumor DNA (ctDNA). This groundbreaking technology is redefining how we detect, monitor, and treat cancer.

The global Circulating Tumor DNA market is set to rise from USD 7.96 billion in 2025 to nearly USD 27.67 billion by 2034, growing at an impressive CAGR of 14.85%.

This surge is fueled by rapid advancements in precision oncology, the rise of targeted therapies, and breakthroughs in next-generation sequencing (NGS) technologies.

Largest Market (2024): North America (51% share)

Fastest-Growing Market: Asia Pacific

Leading Technology: Next-Generation Sequencing (NGS) – 48% share

Top Application: Cancer Diagnosis & Screening – 53% share

Main Sample Type: Blood – 82% share

🧬 What Exactly Is Circulating Tumor DNA (ctDNA)?

ctDNA refers to tiny DNA fragments shed from cancer cells into the bloodstream. These fragments act as non-invasive biomarkers, revealing genetic changes linked to tumors. Through liquid biopsy tests, ctDNA helps doctors detect cancer early, track treatment effectiveness, and monitor for minimal residual disease (MRD) — all without the need for painful tissue biopsies.

In short, ctDNA is the future of precision cancer care, offering real-time insights from just a blood sample.

🚀 What’s Driving the Market Forward?

Rising Cancer Incidence: With cancer cases increasing globally, the demand for fast, accurate, and non-invasive testing methods is skyrocketing.

Next-Gen Technology: Tools like digital PCR and AI-powered sequencing are improving sensitivity, making ctDNA analysis more reliable and accessible.

Venture Investments: Major players like Illumina, Guardant Health, and Bio-Rad are pouring funds into ctDNA innovation.

Liquid Biopsy Revolution: ctDNA tests can detect cancer recurrence months earlier than imaging as seen in recent studies like the VICTORI trial for colorectal cancer.

🔬 Technology Shifts: From Sequencing to Smart Diagnostics

The market is witnessing a massive technological leap. NGS dominates with its ability to scan multiple genes at once, while PCR-based assays are gaining traction for their cost efficiency and clinical validation. Adding AI and Machine Learning into the mix allows for faster, more accurate interpretation of genetic data marking the dawn of smart cancer diagnostics.

🧫 Blood vs. Urine: The Sample Battle

Blood remains the go-to source for ctDNA analysis, holding a whopping 82% share in 2024. It’s minimally invasive, efficient, and rich in tumor DNA. However, urine samples are catching up fast, offering even easier and repeatable ways to detect biomarkers — especially in urological cancers.

🏥 Who’s Leading the Charge?

Clinical laboratories and diagnostic centers lead the ctDNA testing landscape, thanks to their advanced genomics capabilities and validation infrastructure. Meanwhile, biopharma companies are ramping up investments in ctDNA for drug discovery and clinical trials, accelerating the rise of personalized medicine.

🌍 Regional Highlights

North America – The Powerhouse

With 51% of the global share, North America leads the ctDNA market due to its strong healthcare ecosystem and early adoption of cutting-edge diagnostics. The U.S., especially, is making strides with multi-cancer early detection (MCED) initiatives and rapid advancements in digital PCR and NGS platforms.

Asia Pacific – The Rising Star

Expected to grow at the fastest pace, Asia Pacific is seeing a surge in liquid biopsy adoption. Countries like Japan and Singapore are advancing ctDNA research for early cancer detection and national screening programs.

Europe – The Innovator

Europe continues to push boundaries in precision oncology. From Germany’s biotech-driven ecosystem to pan-European collaborations, ctDNA is gaining ground through research partnerships and streamlined regulatory frameworks.

🧠 The Future is Personalized

As ctDNA becomes a cornerstone of modern oncology, its applications will only expand from early cancer screening to therapy optimization and long-term monitoring. The integration of AI, digital health, and liquid biopsy technologies will turn personalized medicine into standard practice worldwide.

✨ Final Thought